AngioDynamics’ pivot toward faster-growing, higher-margin Med Tech platforms could unlock a valuation re-rating, but cash use, manufacturing execution and clinical adoption make the transformation a high-variance investment.
Overview
AngioDynamics designs and sells minimally invasive devices to hospitals, outpatient centers and physician-owned labs, with revenue led by disposable catheters, procedural packs and capital consoles. Its strategic pivot redirects resources from mature vascular-access and surgical products toward Auryon atherectomy, AlphaVac/AngioVac thrombectomy and NanoKnife non-thermal ablation. FY26 sales were $320.2 million, up 9.5%; Med Tech grew 18.4% to $150.0 million, while Med Device rose 2.5% to $170.2 million. In Q1 FY27, sales increased 6.9% to $80.92 million and beat consensus; Med Tech grew 13.2%, adjusted gross margin reached 57.8%, and Adjusted EBITDA rose 127.3% to $5.0 million. The company remains GAAP-loss-making, and cash fell to $34.0 million from $53.9 million at FY26 year-end. **The central catalyst is Med Tech becoming more than 50% of sales in FY27**, supported by clinical adoption and a disclosed U.S. TAM projected to reach $10.9 billion. Management reaffirmed FY27 sales guidance of $336–$341 million and targets $13–$16 million Adjusted EBITDA. At $15.12, the stock trades at 1.84x TTM sales; the report’s five-year probability-weighted target is $23.91, with execution, liquidity and CEO succession as near-term watchpoints.